These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 7353778

  • 1. [Prolactin in serum and anamnestic data of women with cystic disease of the breast (author's transl)].
    Bischoff J, Rebhan EM, Prestele H, Becker H.
    Geburtshilfe Frauenheilkd; 1980 Jan; 40(1):65-71. PubMed ID: 7353778
    [Abstract] [Full Text] [Related]

  • 2. Circadian variation of serum prolactin and TSH of women in health or with mammary carcinoma, fibroadenoma or fibrocystic mastopathy.
    Tarquini B, Gheri R, Romano S, Costa A, Cagnoni M, Lee JK, Halberg F.
    Int J Chronobiol; 1980 Jan; 7(2):101-15. PubMed ID: 7450919
    [Abstract] [Full Text] [Related]

  • 3. Effect of a low-fat diet on hormone levels in women with cystic breast disease. II. Serum radioimmunoassayable prolactin and growth hormone and bioactive lactogenic hormones.
    Rose DP, Cohen LA, Berke B, Boyar AP.
    J Natl Cancer Inst; 1987 Apr; 78(4):627-31. PubMed ID: 3470539
    [Abstract] [Full Text] [Related]

  • 4. Serum prolactin levels in patients with fibrocystic breast disease.
    Peters F, Schuth W, Scheurich B, Breckwoldt M.
    Obstet Gynecol; 1984 Sep; 64(3):381-5. PubMed ID: 6431348
    [Abstract] [Full Text] [Related]

  • 5. Mammary cancer risk: circulating TSH and prolactin, fibrocystic breast disease in chronoepidemiologic perspective.
    Tarquini B, Benvenuti M, Legnaioli M, Bazzani M, Cagnoni M, Halberg F.
    Cancer Detect Prev; 1981 Sep; 4(1-4):525-34. PubMed ID: 7349819
    [Abstract] [Full Text] [Related]

  • 6. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC, Sellwood RA, Knyba RE, Irvine JD.
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract] [Full Text] [Related]

  • 7. Serum prolactin and oestradiol levels in women with cyclical mastalgia.
    Watt-Boolsen S, Andersen AN, Blichert-Toft M.
    Horm Metab Res; 1981 Dec; 13(12):700-2. PubMed ID: 7319468
    [Abstract] [Full Text] [Related]

  • 8. Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154).
    Martin-Comin J, Pujol-Amat P, Cararach V, Davi E, Robyn C.
    Obstet Gynecol; 1976 Dec; 48(6):703-6. PubMed ID: 1036613
    [Abstract] [Full Text] [Related]

  • 9. Effect of a low-fat diet on hormone levels in women with cystic breast disease. I. Serum steroids and gonadotropins.
    Rose DP, Boyar AP, Cohen C, Strong LE.
    J Natl Cancer Inst; 1987 Apr; 78(4):623-6. PubMed ID: 3104646
    [Abstract] [Full Text] [Related]

  • 10. [Mastopathy and breast cancer: is there a typical hormone profile?].
    Völker W, Leipert KP, Gehrlings H, Stauch G, von zur Mühlen A, Schneider J.
    Geburtshilfe Frauenheilkd; 1986 May; 46(5):284-9. PubMed ID: 3087811
    [Abstract] [Full Text] [Related]

  • 11. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
    Holtkamp W, von Heyden D, Rauschecker H, Nagel GA.
    Schweiz Med Wochenschr; 1983 Oct 15; 113(41):1513-20. PubMed ID: 6635641
    [Abstract] [Full Text] [Related]

  • 12. [Interaction between beta-endorphin, steroids and peptide hormones in fibrocystic lesions of the female breast].
    Schurz B.
    Wien Klin Wochenschr Suppl; 1991 Oct 15; 187():3-26. PubMed ID: 1648846
    [Abstract] [Full Text] [Related]

  • 13. [Serum prolactin level in patients with mastopathy. Clinical significance].
    Peters F, Breckwoldt M.
    Verh Dtsch Ges Pathol; 1985 Oct 15; 69():401-4. PubMed ID: 3938116
    [No Abstract] [Full Text] [Related]

  • 14. Cystic disease, family history of breast cancer, and use of oral contraceptives.
    Vakil DV, Elinson L, Morgan RW.
    Cancer Detect Prev; 1981 Oct 15; 4(1-4):511-5. PubMed ID: 7349817
    [Abstract] [Full Text] [Related]

  • 15. Beta-endorphin, steroids, and prolactin. Immunoassay in breast cysts and blood.
    Schön HJ, Schurz B, Wenzl R, Knogler W, Kubista E.
    Arch Pathol Lab Med; 1993 Mar 15; 117(3):248-53. PubMed ID: 8442670
    [Abstract] [Full Text] [Related]

  • 16. Oral contraception and breast pathology.
    Ragni N, Boccardo E, Viglino S, Larosa E.
    Acta Eur Fertil; 1981 Jun 15; 12(2):141-63. PubMed ID: 6794288
    [Abstract] [Full Text] [Related]

  • 17. [Plasma levels of prolactin in women with dysplasia and tumors of the breast (fibroadenoma and carcinoma of the breast)].
    Iturburu Belmonte IM, Basáñez Amuchastegui A, Jiménez Jiménez E, López de Tejada Cabeza I, Goicoechea García J, Méndez Martín J.
    Rev Quir Esp; 1988 Jun 15; 15(1):17-21. PubMed ID: 3153353
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of benign fibrocystic disease of the breast with 2-bromo-alpha-ergocryptine (CB 154).
    Santoro C, Cappa M, Moretti C, Fabbri A, La Vecchia V, Romano Marcellino L, Fraioli F.
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct 15; 20(10):479-81. PubMed ID: 6815107
    [Abstract] [Full Text] [Related]

  • 19. [Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline].
    Mussa A, Sandrucci S, Dogliotti L.
    Minerva Med; 1979 Nov 17; 70(51):3493-8. PubMed ID: 522987
    [Abstract] [Full Text] [Related]

  • 20. Prolactin and breast cancer risk.
    Ingram DM, Nottage EM, Roberts AN.
    Med J Aust; 1990 Oct 15; 153(8):469-73. PubMed ID: 2215338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.